Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,872 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Tamaki N, Tada T, Kurosaki M, Yasui Y, Ochi H, Mashiba T, Sakamoto A, Marusawa H, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kobashi H, Kusakabe A, Furuta K, Arai H, Nonogi M, Ogawa C, Sato T, Tamada T, Nakamura S, Hasebe C, Tsuchiya K, Izumi N. Tamaki N, et al. Among authors: nakamura s. Invest New Drugs. 2022 Dec;40(6):1290-1297. doi: 10.1007/s10637-022-01303-w. Epub 2022 Sep 24. Invest New Drugs. 2022. PMID: 36152108
Hepatocellular carcinoma occurring in hepatobiliary fibropolycystic disease.
Kinugasa H, Nouso K, Kobayashi Y, Yasunaka T, Onishi H, Nakamura S, Shiraha H, Takayama H, Toshimori J, Kuwaki K, Hagihara H, Miyake Y, Ikeda F, Takaki A, Kobashi H, Yamamoto K. Kinugasa H, et al. Among authors: nakamura s. Hepatol Res. 2011 Mar;41(3):277-81. doi: 10.1111/j.1872-034X.2010.00761.x. Hepatol Res. 2011. PMID: 21338456
Prognostic model for hepatocellular carcinoma with time-dependent factors.
Kuwaki K, Nouso K, Kobayashi Y, Nakamura S, Ito YM, Iwadou S, Hagihara H, Yasunaka T, Toshimori J, Miyatake H, Miyoshi K, Onishi H, Miyake Y, Shoji B, Takaki A, Shiraha H, Iwasaki Y, Kobashi H, Yamamoto K. Kuwaki K, et al. Among authors: nakamura s. Acta Med Okayama. 2011 Feb;65(1):11-9. doi: 10.18926/AMO/43825. Acta Med Okayama. 2011. PMID: 21339791 Free article.
Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein.
Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Nouso K, et al. Among authors: nakamura s. J Gastroenterol Hepatol. 2011 Jul;26(7):1195-200. doi: 10.1111/j.1440-1746.2011.06720.x. J Gastroenterol Hepatol. 2011. PMID: 21410750
Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine.
Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Kobashi H, et al. Among authors: nakamura s. Hepatol Res. 2011 May;41(5):405-16. doi: 10.1111/j.1872-034X.2011.00785.x. Epub 2011 Mar 21. Hepatol Res. 2011. PMID: 21435126
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K; Okayama Liver Cancer Group. Miyahara K, et al. Among authors: nakamura s. Br J Cancer. 2013 Oct 15;109(8):2072-8. doi: 10.1038/bjc.2013.554. Epub 2013 Sep 17. Br J Cancer. 2013. PMID: 24045661 Free PMC article.
Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib.
Adachi T, Nouso K, Miyahara K, Oyama A, Wada N, Dohi C, Takeuchi Y, Yasunaka T, Onishi H, Ikeda F, Nakamura S, Shiraha H, Takaki A, Takabatake H, Fujioka SI, Kobashi H, Takuma Y, Iwadou S, Uematsu S, Takaguchi K, Hagihara H, Okada H; Okayama Liver Cancer Group. Adachi T, et al. Among authors: nakamura s. J Gastroenterol Hepatol. 2019 Jun;34(6):1081-1087. doi: 10.1111/jgh.14535. Epub 2018 Dec 10. J Gastroenterol Hepatol. 2019. PMID: 30402928
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y. Tada T, et al. Among authors: nakamura s. Liver Int. 2020 Apr;40(4):968-976. doi: 10.1111/liv.14405. Epub 2020 Mar 1. Liver Int. 2020. PMID: 32064740
10,872 results
You have reached the last available page of results. Please see the User Guide for more information.